Etoricoxib provides long lasting pain relief after surgery

Apr 15, 2009

Oral etoricoxib is at least as effective as other drugs commonly used for pain relief after surgery. A Cochrane Systematic Review has confirmed the effectiveness of the drug, which is sold under the brand name of Arcoxia.

Developed as an alternative to conventional non-steroidal anti-inflammatory drugs (NSAIDs), which can cause intestinal bleeding, "coxibs" are licensed for chronic and acute pain. In in England, 64,000 prescriptions for the highest etoricoxib dose (120 mg) were issued in 2007.

Five studies with 880 participants were included in the review. Four followed patients experiencing pain due to tooth extractions. The fifth focused on patients with pain following orthopaedic surgery. For two thirds of patients etoricoxib provided effective for 20 hours, compared to one in ten patients for just two hours with a placebo.

"Single dose oral etoricoxib produces high levels of good quality pain relief after surgery," says lead researcher Andrew Moore, of the Pain Research and Nuffield Department of Anaesthetics at the University of Oxford.

Moore adds that the long lasting action of etoricoxib makes it qualitatively different from other coxibs and ibuprofen. "We have effective analgesics, but often fail to deliver them effectively. A longer time before remedication is likely to benefit patients by providing long-lasting pain relief, and reduce demands on nursing staff," he says.

Sheena Derry, another author, comments, "Acute pain studies like these have been done for over 60 years, using similar patients, similar methods, and the same outcomes. This is just one of a series of new reviews and updates in acute pain aiming to cover one whole section of the British National Formulary. The end product should help providers construct consistent and effective ways of delivering good pain relief to patients."

Source: Wiley (news : web)

Explore further: Evidence lacking for long-term opioid use in low back pain

add to favorites email to friend print save as pdf

Related Stories

Study: Patients often don't report pain

Feb 13, 2006

A Rochester, Minn., study finds more than 20 percent of people with chronic pain don't seek medical help, suggesting many have unmet pain care needs.

Chronic pain should be considered a disease

Feb 15, 2008

The concept that chronic pain is a disease in its own right is leading to new specific treatments aimed at physical, psychological, and environmental components of this major disease, including genetic predisposition, according ...

Recommended for you

Pyridoxine-doxylamine drug safety data lacking

16 hours ago

(Medical Xpress)—The most commonly prescribed drug for pregnant women suffering from morning sickness in their first trimester does not prevent birth defects even though drug safety data says it does, according to research ...

FDA approves new type 2 diabetes drug

Apr 15, 2014

(HealthDay)—Millions of Americans with type 2 diabetes have a new treatment option with the U.S. Food and Drug Administration's approval Tuesday of a once-weekly injectable drug, Tanzeum.

User comments : 0

More news stories

Down's chromosome cause genome-wide disruption

The extra copy of Chromosome 21 that causes Down's syndrome throws a spanner into the workings of all the other chromosomes as well, said a study published Wednesday that surprised its authors.

Simplicity is key to co-operative robots

A way of making hundreds—or even thousands—of tiny robots cluster to carry out tasks without using any memory or processing power has been developed by engineers at the University of Sheffield, UK.

Progress in the fight against quantum dissipation

(Phys.org) —Scientists at Yale have confirmed a 50-year-old, previously untested theoretical prediction in physics and improved the energy storage time of a quantum switch by several orders of magnitude. ...